Company Portage Biotech Inc OTC Bulletin Board

Equities

CA09852M1014

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Shareholders

Holdings

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 15	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI
Apr. 12	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI

Portage Biotech Inc. develops pharmaceutical and biotech products through to clinical proof of concept focusing on unmet clinical needs. After proof of concept, the Company will look to sell or license the products to various pharmaceutical companies for further development through to commercialization. The Company's research and development work is primarily carried out through approximately two subsidiaries, including Portage Pharmaceuticals Ltd (PPL) and Biohaven Pharmaceutical Holding Company Limited (Biohaven). The Company also holds interests in Sentien Biotechnologies Inc., a regenerative medicine company. PPL focuses on discovering and developing cell permeable peptide (CPP) therapies to normalize gene expression, restore function and improve medical outcomes. Biohaven is engaged in the identification and development of glutamatergic agents for treatment-resistant neuropsychiatric disorders. Its product pipeline includes PPL-003, BHV-0223 and BHV-4157.

Managers	Title	Age	Since
Ian Walters CEO	Chief Executive Officer	57	16-07-31
Allan Shaw DFI	Director of Finance/CFO	59	20-05-11
Steve Innaimo COO	Chief Operating Officer	-	19-01-07
Robert Kramer CTO	Chief Tech/Sci/R&D Officer	72	19-01-07
Justin Fairchild PRN	Corporate Officer/Principal	-	22-08-17
Brian Wiley PRN	Corporate Officer/Principal	56	22-02-14
Joseph Ciavarella AUD	Comptroller/Controller/Auditor	68	19-12-31

Members of the board	Title	Age	Since
Gregory Bailey FOU	Founder	68	72-12-31
Steven Mintz BRD	Director/Board Member	57	16-04-05
Robert Glassman BRD	Director/Board Member	62	-
Mark Simon BRD	Director/Board Member	62	22-02-14
Ian Walters CEO	Chief Executive Officer	57	16-07-31
Linda Kozick BRD	Director/Board Member	66	22-02-14

Name	Equities	%	Valuation
Gregory Bailey 17.20 %	3,402,195	17.20 %	806 320 $
Estate of Mellon James 15.33 %	3,032,821	15.33 %	718 779 $
Armistice Capital LLC 8.420 %	1,665,885	8.420 %	394 815 $
Ian Walters 1.246 %	246,516	1.246 %	58 424 $
Bison Wealth LLC 1.079 %	213,398	1.079 %	50 575 $
Robert Kramer 0.7431 %	147,009	0.7431 %	34 841 $
Steven Mintz 0.2796 %	55,311	0.2796 %	13 109 $
Peak6 Investments LLC 0.2793 %	55,263	0.2793 %	13 097 $
Millennium Management LLC 0.1659 %	32,827	0.1659 %	7 780 $
Renaissance Technologies LLC 0.1600 %	31,663	0.1600 %	7 504 $

Name	Equities	%	Valuation
INTENSITY THERAPEUTICS, INC. 4.70%	644,229	4.70%	2,528,599 $

Portage Biotech, Inc.

Clarence Thomas Building

VG1110, Road Town

http://www.portagebiotech.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.11%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research